Cytokinetics reports strong Q1 2026 launch of MYQORZO with $4.8M sales and positive trial results for aficamten.

Cytokinetics launched MYQORZO (aficamten) in the U.S. in January 2026, achieving $4.8 million in net product revenue and strong early adoption by healthcare providers. The company announced positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), meeting key endpoints in symptom improvement and exercise performance. MYQORZO also received European Commission approval, with a planned launch in Germany in Q2 2026. Cytokinetics maintains its 2026 financial guidance despite a net loss of $206 million in Q1, driven by commercial launch costs and R&D expenses, while advancing multiple clinical trials globally.